|
Accrued
expenses and other liabilities, summarized by major category, consist of the following for years ended December 31, 2021 and 2020 (in
thousands):
Schedule
of Accrued Expenses
| |
|
|
2021 |
|
|
|
2020 |
|
| |
|
As
of December 31, |
|
| |
|
2021 |
|
|
2020 |
|
| Payroll
and incentives |
|
$ |
1,343 |
|
|
$ |
1,094 |
|
| General
and administrative expenses |
|
|
195 |
|
|
|
280 |
|
| Research
and development expenses |
|
|
381 |
|
|
|
778 |
|
|
Deferred revenue and other deferred liabilities *
|
|
|
932 |
|
|
|
643 |
|
| Total |
|
$ |
2,851 |
|
|
$ |
2,795 |
|
| * |
At
December 31, 2021, the balance included approximately $899 thousand related to the CFF Agreement’s deferred liability and approximately
$33 thousand is deferred revenue related to the Genentech feasibility study agreement. At December 31, 2020, the balance included
approximately $577 thousand related to the CFF Agreement’s deferred liability and approximately $67 thousand of deferred revenue
related to the Genentech feasibility study agreement. |
|